Prognostic Impact of High-Risk Pathologic Features in HPV-Related Oropharyngeal Squamous Cell Carcinoma and Tobacco Use

Abstract

Objectives

To assess the impact of pathologic features and chronic tobacco use on human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma (OPSCC).

Study Design

Case series with chart review.

Setting

Single tertiary care referral center.

Subject and Methods

A total of 301 patients were treated for OPSCC from 2008 to 2016. Clinical and pathologic T and N stage, American Joint Committee on Cancer (AJCC) stage (seventh and eighth edition staging manuals), cigarette pack years, alcohol use, and presence of extranodal extension (ENE), perineural invasion (PNI), or lymphovascular invasion (LVI) were assessed. Patients were stratified into HPV negative, HPV-positive heavy smokers (≥20 pack years), and HPV-positive nonsmokers. Five-year survival by Kaplan-Meier method was assessed.

Results

Of the HPV-positive patients, 97 were nonsmokers and 73 were heavy smokers. HPV-positive heavy smokers had significantly decreased survival compared to their nonsmoking counterparts (P = .02). The presence of ENE was associated with a significantly decreased 5-year survival (P = .02) in heavy smokers relative to nonsmokers in HPV-positive patients. Furthermore, for the AJCC eighth edition, clinically stage 1 HPV-positive heavy smokers had significantly decreased survival relative to nonsmokers (P = .01).

Conclusions

This series highlights the potential need for more aggressive therapy for HPV-positive patients with extensive tobacco use under the new staging system.

Keywords

oropharynx oropharyngeal squamous cell carcinoma head and neck squamous cell carcinoma HPV tobacco use smoking survival AJCC staging

Get full access to this article

View all access options for this article.

References

Siegel

Miller

Jemal

Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.

Viens

Henley

Watson

et al . Human papillomavirus–associated cancers—United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2016;65:661-666.

Chaturvedi

Engels

Pfeiffer

et al . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294-4301.

Gillison

Zhang

Jordan

et al . Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012;30:2102-2111.

Deschler

Richmon

Khariwala

Ferris

Wang

MB.

The “new” head and neck cancer patient-young, nonsmoker, nondrinker, and HPV positive: evaluation. Otolaryngol Head Neck Surg. 2014;151:375-380.

Ang

Harris

Wheeler

et al . Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.

Fakhry

Zhang

Nguyen-Tan

et al . Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014;32:3365-3373.

Platek

Jayaprakash

Merzianu

et al . Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation. Laryngoscope. 2016;126:2733-2738.

Kumar

Cordell

Lee

et al . EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26:3128-3137.

10.

Hafkamp

Manni

Haesevoets

et al . Marked differences in survival rate between smokers and nonsmokers with HPV 16–associated tonsillar carcinomas. Int J Cancer. 2008;122:2656-2664.

11.

Maxwell

Kumar

Feng

et al . Tobacco use in human papillomavirus–positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010;16:1226-1235.

12.

Peterson

Bellile

Wolf

et al . Cigarette use, comorbidities, and prognosis in a prospective head and neck squamous cell carcinoma population. Head Neck. 2016;38:1810-1820.

13.

Ajmani

Nocon

Wang

Bhayani

MK.

Assessment of adjuvant therapy in resected head and neck cancer with high-risk features. Oral Oncol. 2017;74:15-20.

14.

Mirghani

Amen

Blanchard

et al . Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. Int J Cancer. 2015;136:1494-1503.

15.

Adelstein

Gillison

Pfister

et al . NCCN guidelines insights: head and neck cancers, Version 2.2017. J Natl Compr Canc Netw. 2017;15:761-770.

16.

Amin

, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. 8th ed. Chicago, IL: American Joint Committee on Cancer, Springer; 2017.

17.

Cramer

Hicks

Rademaker

Patel

Samant

Validation of the eighth edition American Joint Committee on Cancer staging system for human papillomavirus–associated oropharyngeal cancer. Head Neck. 2018;40:457-466.